Nutriband (NTRB) Stock Price, News & Analysis

Company Overview

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Key Stats

• Today's Range: $3.03 to $3.19
• 50-Day Range: $2.90 to $4.08
• 52-Week Range: $2.90 to $10.65
• Volume: 11,387 shs
• Average Volume: 12,687 shs
• Market Capitalization: $37.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Nutriband Stock Analysis - MarketRank™

Nutriband scored higher than 2% of companies evaluated by MarketBeat, and ranked 841st out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Nutriband has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Nutriband has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nutriband is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nutriband is -1.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nutriband has a P/B Ratio of 5.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.08% of the float of Nutriband has been sold short.

Short Interest Ratio / Days to Cover

Nutriband has a short interest ratio ("days to cover") of 19.74, which indicates bearish sentiment.

Change versus previous month

Short interest in Nutriband has recently increased by 3.69%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nutriband does not currently pay a dividend.

Dividend Growth

Nutriband does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added Nutriband to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nutriband insiders have not sold or bought any company stock.

Percentage Held by Insiders

52.21% of the stock of Nutriband is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.70% of the stock of Nutriband is held by institutions.

Company Calendar

• Last Earnings: 6/11/2026
• Today: 7/05/2026
• Fiscal Year End: 1/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NTRB
• CIK: 1676047
• Web: nutriband.com
• Phone: (407) 377-6695
• Fax: N/A
• Employees: 10
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($2.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.23 million
• Net Margins: -448.25%
• Pretax Margin: -448.31%
• Return on Equity: -112.64%
• Return on Assets: -97.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.26
• Quick Ratio: 5.11

Sales & Book Value

• Annual Sales: $2.04 million
• Price / Sales: 18.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.55 per share
• Price / Book: 5.56

Miscellaneous

• Outstanding Shares: 12,160,000
• Free Float: 5,809,000
• Market Cap: $37.21 million
• Optionable: Not Optionable
• Beta: 1.93